PK-DB an open database for pharmacokinetics information from clinical trials as well as pre-clinical research. The focus of PK-DB is to provide high-quality pharmacokinetics data enriched with the required meta-information for computational modeling and data integration.

Snapshot img

Preclinical Software for Physiology DA and AS Market Size 2025-2029

The preclinical software for physiology da and as market size is forecast to increase by USD 4.38 billion, at a CAGR of 6% between 2024 and 2029.

The Preclinical Software for Physiology market is experiencing significant growth, driven by the increasing role of bioinformatics tools and software in preclinical research. The digitalization trend in scientific research is leading to an increased demand for advanced software solutions that can analyze complex physiological data. However, this market faces challenges due to the stringent ethical frameworks governing the use of animals in preclinical research. Bioinformatics tools and software are becoming essential components of preclinical research, enabling researchers to process, analyze, and interpret vast amounts of data generated from various experiments. The digitalization of preclinical research is accelerating, with an increasing number of institutions and organizations adopting digital solutions to streamline their research processes and improve efficiency.
Despite these opportunities, the use of animals in preclinical research remains a contentious issue, with ethical concerns surrounding animal welfare and the validity of animal models for human diseases. Strict regulatory frameworks and public scrutiny are putting pressure on researchers to justify the use of animals and to ensure that they are treated ethically. Companies seeking to capitalize on this market must navigate these ethical challenges while providing innovative software solutions that meet the evolving needs of the preclinical research community.

What will be the Size of the Preclinical Software for Physiology DA and AS Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

The preclinical software market for physiology DA and AS is a dynamic and evolving landscape, characterized by continuous advancements and innovations. This market encompasses a range of solutions, including toxicokinetic software, pharmacodynamics modeling, physiological modeling software, regulatory compliance software, bioavailability prediction tools, and quantitative systems pharmacology. These tools employ various techniques such as model calibration, simulation, physiologically based pharmacokinetics, efficacy prediction models, pharmacokinetic modeling, compartmental modeling, and uncertainty quantification. These methodologies are seamlessly integrated into the software, enabling researchers to explore drug disposition, metabolism, and interaction with biological systems. Preclinical data management, dose-response curve modeling, and preclinical safety assessment are integral components of these solutions.

Systems pharmacology modeling, adme prediction software, model validation procedures, and parameter estimation methods are also essential elements, ensuring accurate and reliable results. Data visualization dashboards facilitate the interpretation of complex data sets, providing valuable insights into drug behavior and potential therapeutic applications. Time-course data analysis, drug absorption simulation, and sensitivity analysis methods further enhance the capabilities of these software solutions, enabling researchers to make informed decisions in the drug development process. The ongoing integration of these advanced techniques and tools into preclinical software continues to reshape the market, offering significant benefits across various sectors, including pharmaceuticals, biotechnology, and academia. The evolving patterns in this market reflect the growing demand for more accurate, efficient, and cost-effective preclinical research solutions.

How is this Preclinical Software for Physiology DA and AS Industry segmented?

The preclinical software for physiology DA and AS industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

End-user

  Industrial labs and CROs
  Academic government and research labs


Deployment

  On-premises
  Cloud
  hybrid


Application

  Physiology Research
  Drug Development and Safety Testing
  Behavioral Studies
  Other Applications (e.g., Veterinary, Educational)


Type of Software

  Data Acquisition Software
  Data Analysis Software
  Integrated Platforms


Organization Size

  Small and Medium Enterprises (SMEs)
  Large Enterprises


Technology

  AI/ML-Integrated Software
  Traditional Software


Pricing Model

  Subscription-Based
  Perpetual License
  Freemium or Pay-per-Use


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    The Netherlands
    UK

STOREDB database is a repository for data used by the international radiobiology community, archiving and sharing primary data outputs from research on low dose radiation. It also provides a directory of bioresources and databases for radiobiology projects containing information and materials that investigators are willing to share. STORE supports the creation of a low dose radiation research commons.

Database: Systematic review of preclinical studies on the neutrophils

Snapshot img

Preclinical CRO Market Size 2025-2029

The preclinical cro market size is forecast to increase by USD 2.73 billion, at a CAGR of 8.1% between 2024 and 2029.

The Preclinical Contract Research Organizations (CRO) market is experiencing significant growth, driven by the increasing prevalence of chronic diseases and the subsequent surge in the number of clinical trials. This trend is fueled by the rising demand for new and innovative therapeutic solutions, particularly in areas such as oncology, neurology, and cardiovascular diseases. However, the industry faces challenges, including intellectual property issues that hinder market expansion. Intellectual property disputes pose a significant challenge to the market, as conflicts over patents and proprietary data can lead to costly litigation and delays in bringing new therapies to market. Additionally, the high costs associated with preclinical research and development, coupled with the increasing complexity of clinical trials, necessitate strategic partnerships between CROs and pharmaceutical companies to manage risks and optimize resources. To capitalize on market opportunities and navigate challenges effectively, CROs must focus on innovation and collaboration. This includes investing in advanced technologies, such as artificial intelligence and machine learning, to streamline processes, improve data analysis, and enhance overall efficiency. Furthermore, strategic alliances with academic institutions, research organizations, and technology providers can help CROs expand their capabilities, broaden their expertise, and strengthen their competitive position. By addressing these challenges and embracing innovation, Preclinical CROs can effectively contribute to the development of new therapies and advancements in healthcare.

What will be the Size of the Preclinical CRO Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free SampleThe preclinical Contract Research Organization (CRO) market continues to evolve, integrating various sectors to support the biotechnology and pharmaceutical industries in bringing new drugs to market. Study management and statistical analysis are crucial components, ensuring the design and execution of preclinical studies adhere to rigorous standards. Drug elimination, safety assessment, and analytical chemistry play essential roles in understanding drug properties and potential risks. Clinical trial monitoring, mass spectrometry, and data analysis facilitate efficient and accurate data collection and interpretation. Drug discovery relies on these services to optimize candidate selection and reduce development timelines. Cell culture and contract research organizations provide vital resources for in vitro and animal studies, enabling pharmacodynamic and pharmacokinetic evaluations. Electronic data capture, GLP compliance, and data management are integral to maintaining regulatory requirements. Biotechnology and pharmaceutical industries leverage these services for clinical trial design, protocol development, biomarker analysis, and NDA application support. Preclinical studies encompass various applications, including genotoxicity testing, drug distribution, pharmaceutical development, and regulatory affairs. The ongoing unfolding of market activities involves continuous innovation and integration of advanced technologies, such as image analysis, tissue engineering, and bioanalytical services. In vivo models, reproductive toxicity testing, and carcinogenicity testing are crucial components of safety assessment. Drug absorption, immunotoxicology testing, and efficacy evaluation contribute to the overall understanding of drug properties and potential therapeutic applications. In summary, the market is characterized by continuous innovation and integration of various services to support the biotechnology and pharmaceutical industries. From study management and statistical analysis to drug discovery and regulatory affairs, these services play essential roles in bringing new drugs to market. The market's evolving nature ensures a dynamic landscape, with ongoing advancements and applications across various sectors.

How is this Preclinical CRO Industry segmented?

The preclinical cro industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments. End-userP and B companiesMedical device companiesAcademic institutesServiceToxicology testingBioanalysis and DMPK studiesCompound managementOthersGeographyNorth AmericaUSCanadaMexicoEuropeFranceGermanyItalyUKAPACChinaIndiaJapanRest of World (ROW)

By End-user Insights

The p and b companies segment is estimated to witness significant

The Preclinical Software for Physiology Data Assessment and Animal Supervision Market is witnessing steady growth, driven by the increasing demand for accurate preclinical research, advancements in data analytics, and stringent regulatory compliance requirements. The adoption of AI-driven software, automation in animal studies, and real-time monitoring solutions is significantly enhancing the efficiency and reliability of preclinical assessments.Several factors contribute to this market expansion, including rising R&D investments in pharmaceuticals and biotechnology, advancements in physiological data collection technologies, and regulatory mandates emphasizing ethical animal supervision and data transparency. Additionally, the integration of AI, machine learning, and cloud computing is improving data analysis and decision-making, further driving market growth.The market is segmented based on software type (data analysis, monitoring, compliance management), application (toxicology, drug discovery, neuroscience research), and end-users (pharmaceutical companies, contract research organizations, academic institutions, and research laboratories). North America currently leads the market due to high investments in drug discovery and strong regulatory frameworks, while the Asia-Pacific region is emerging as a lucrative market due to increasing clinical research activities.Key players in the industry include Harvard Bioscience, DSI, ADInstruments, Noldus, and BIOPAC Systems, among others, who continue to innovate and expand their product offerings to meet the evolving needs of the market.

This database compiles systematic reviews (SRs) of animal studies (i.e., reviews that focused exclusively on non-human animal research, or reviews that included animal studies along with human studies). This database was developed using a rigorous, systematic approach and it covers a broad range of research fields: preclinical research, toxicology, environmental health, and veterinary medicine. The goals of this database are to: (1) provide a comprehensive collection of animal study SRs to advance systematic review methods development; (2) enable researchers to avoid duplication of effort and, thus, reduce research waste by identifying published SRs of animal studies that may already address a research question; and (3) aid in the creation of evidence maps, usually designed as interactive figures of study characteristics.

The SRs included in the database were identified using a comprehensive search strategy (see data) in MEDLINE (via PubMed), Embase (via Ovid), and Web of Science. The records included in the animal studies SR database meet the following eligibility criteria: 1. The reference aims to systematically review the literature. The title or abstract states this aim using terminology such as “literature review,” “literature overview,” “systematic review,” “systematic survey,” or “meta-analysis.” 2. The reference summarizes the results of studies in laboratory or experimental animals to investigate human or animal health. 3. The reference reports the eligibility criteria for the primary studies, specifies search terms, and the search is performed in at least one specified database/electronic source (e.g., PubMed). 4. A full text version of the reference is publicly available.

There were no restrictions in language or publication date.

Version 1.0 covers data through 13 February 2018 Version 1.1 covers data through 18 June 2019

RxNorm provides normalized names for clinical drugs and links its names to many of the drug vocabularies commonly used in pharmacy management and drug interaction software, including those of First Databank, Micromedex, and Gold Standard Drug Database. By providing links between these vocabularies, RxNorm can mediate messages between systems not using the same software and vocabulary.

The attached supplemental data has been used for the following preprint: https://doi.org/10.1101/2024.12.15.628103 Detailed description of data collection, aggregation and analysis can be found in the publication. Abstract: Experimental mouse models are indispensable for the preclinical development of cancer immunotherapies, whereby complex interactions in the tumor microenvironment (TME) can be somewhat replicated. Despite the availability of diverse models, their predictive capacity for clinical outcomes remains largely unknown, posing a hurdle in the translation from preclinical to clinical success. This study systematically reviews and meta-analyzes clinical trials of chimeric antigen receptor (CAR)-T cell monotherapies with their corresponding preclinical studies. Adhering to PRISMA guidelines, a comprehensive search of PubMed and ClinicalTrials.gov was conducted, identifying 422 clinical trials and 3157 preclinical studies. From these, 105 clinical trials and 180 preclinical studies, accounting for 44 and 131 distinct CAR constructs, respectively, were included. Patients’ responses varied based on the target antigen, expectedly with higher efficacy and toxicity rates in hematological cancers. Preclinical data analysis revealed homogenous and antigen-independent efficacy rates. Our analysis revealed that only 4 % (n = 12) of mouse studies used syngeneic models, highlighting their scarcity in research. Three logistic regression models were trained on CAR structures, tumor entities, and experimental settings to predict treatment outcomes. While the logistic regression model accurately predicted clinical outcomes based on clinical or preclinical features (Macro F1 and AUC > 0.8), it failed in predicting preclinical outcomes from preclinical features (Macro F1 < 0.5, AUC < 0.6), indicating that preclinical studies may be influenced by experimental factors not accounted for in the model. These findings underscore the need to better understand the experimental factors enhancing the predictive accuracy of mouse models in preclinical settings.

Introduction

Global Preclinical CRO Market size is expected to be worth around US$ 10.5 Billion by 2032 from US$ 5.2 Billion in 2023, growing at a CAGR of 7.5% during the forecast period from 2023 to 2032. In 2022, North America led the market, achieving over 47.50% share with a revenue of US$ 2.47 Billion.

This market's expansion is largely fueled by heightened investments in drug discovery and the increased inclination towards outsourcing preclinical studies to CROs that provide specialized services such as bioanalysis, toxicology testing, and drug metabolism and pharmacokinetic (DMPK) studies.

Driving factors for the preclinical CRO market include the rising prevalence of chronic diseases, which necessitates new pharmaceuticals, thus enhancing the demand for preclinical research. North America leads in market share due to its advanced healthcare infrastructure and the presence of major pharmaceutical firms investing in R&D. Conversely, the Asia Pacific is poised for rapid growth, driven by cost efficiencies and a regulatory environment conducive to outsourcing preclinical studies.

Challenges such as stringent regulatory standards imposed by bodies like the U.S. FDA and the European Medicines Agency (EMA) could impede market growth by complicating the drug approval processes.

Parexel International Corporation, a prominent clinical research organization, has significantly bolstered its market position through acquisitions, strategic alliances, and technology advancements. In July 2021, EQT Private Equity and Goldman Sachs Asset Management acquired Parexel for $8.5 billion, aiming to expand its global footprint and enhance services like decentralized clinical trials and data management.

In August 2023, Parexel entered a strategic alliance with Partex, leveraging artificial intelligence (AI) and big data to improve biopharmaceutical clients’ project success rates by discovering new potential disease applications for their assets.

Additionally, in January 2024, Parexel partnered with the Japanese Foundation for Cancer Research to enhance access to oncology clinical trials in Japan, increasing the efficiency of clinical research and expanding patient treatment options.

The sector continues to experience significant global consolidation, as evidenced by FHI Clinical’s acquisition of Triclinium Clinical Development’s operations in South Africa and the purchase of Syneos Health by a consortium including Elliott Investment Management, Patient Square Capital, and Veritas Capital for around $7.1 billion. These mergers and acquisitions aim to enhance service capabilities and broaden geographic coverage.

An open preclinical PET dataset. This dataset has been measured with the preclinical Siemens Inveon PET machine. The measured target is a (naive) rat with an injected dose of 21.4 MBq of FDG. The injection was done intravenously (IV) to the tail vein. No specific organ was investigated, but rather the glucose metabolism as a whole. The examination is a 60 minute dynamic acquisition. The measurement was conducted according to the ethical standards set by the University of Eastern Finland.

The dataset contains the original list-mode data, the (dynamic) sinogram created by the Siemens Inveon Acquisition Workplace (IAW) software (28 frames), the (dynamic) scatter sinogram created by the IAW software (28 frames), the attenuation sinogram created by the IAW software and the normalization coefficients created by the IAW software. Header files are included for all the different data files.

For documentation on reading the list-mode binary data, please ask Siemens.

This dataset can be used in the OMEGA software, including the list-mode data, to import the data to MATLAB/Octave, create sinograms from the list-mode data and reconstruct the imported data. For help on using the dataset with OMEGA, see the wiki.

SI Data Files for Original Research Article "Regulatory Toxicology and Pharmacology: Retrospective analysis of the potential use of virtual control groups in preclinical toxicity assessment using the eTOX database".

These data constitute the supplementary material to the manuscript and are required as input for the Jupyter notebooks that contain the code for reproducing reported results.

SI Data Files for Original Research Article "Regulatory Toxicology and Pharmacology: Statistical analysis of preclinical inter-species concordance of histopathological findings in the eTOX database".

This is a preclinical positron emission tomography (PET) dataset containing the list-mode data of a NEMA image quality phantom measured with the preclinical Siemens Inveon PET scanner. Included are the list-mode datafile (.lst), sinogram file (.scn) created by the Siemens Inveon Acquisition workplace (IAW) software, MAP-OSEM3D reconstruction (.img) created by IAW, scatter correction sinogram (_sct.scn) created by IAW and the attenuation correction UMAP-file (.img) created by IAW. All the corresponding header files are included that contain all the relevant information, with the exception of reading the binary list-mode data. For documentation on reading the list-mode binary data, please ask Siemens.

No normalization data is included in this dataset. You can, however, use the normalization data from Preclinical PET data.

This dataset can be used in the OMEGA software, including the list-mode data, to import the data to MATLAB/Octave, create sinograms from the list-mode data and reconstruct the imported data. For help on using the dataset with OMEGA, see the wiki.

The CT data, that was used to create the UMAP-file, is available from https://zenodo.org/record/4646835.

The measurement data was collected by Jarmo Teuho.

Reports paper Risk_Benefit Orally Bioavailable Flubendazole Formulationreports containing full description of methods and all data of toxicity studies and pharmacokinetic studies described in the paper

The preclinical contract research organization (CRO) market, valued at $7.10 billion in 2025, is poised for substantial growth, exhibiting a compound annual growth rate (CAGR) of 7.44% from 2025 to 2033. This expansion is fueled by several key drivers. The increasing complexity of drug development necessitates outsourcing of preclinical studies to specialized CROs, allowing pharmaceutical and biotechnology companies to focus on core competencies. Furthermore, the rising prevalence of chronic diseases globally is driving demand for new therapeutic interventions, thereby increasing the need for robust preclinical testing. Technological advancements, such as the adoption of patient-derived organoid (PDO) and patient-derived xenograft (PDX) models, are significantly enhancing the accuracy and relevance of preclinical data, further stimulating market growth. The market is segmented by service (toxicology testing, bioanalysis, safety pharmacology, and other services), model type (PDO and PDX models), and end-user (biopharmaceutical companies, research institutes, and universities). North America currently holds a significant market share, driven by robust research infrastructure and a high concentration of biopharmaceutical companies. However, Asia Pacific is expected to witness significant growth due to rising investments in healthcare infrastructure and a growing pharmaceutical industry. Competitive pressures among established players like Charles River Laboratories, Labcorp Drug Development, and Thermo Fisher Scientific, alongside emerging CROs, are likely to intensify. The preclinical CRO market's growth trajectory is influenced by several factors. Stringent regulatory requirements for drug approval necessitate rigorous preclinical testing, leading to increased demand for CRO services. The growing adoption of personalized medicine approaches, requiring tailored preclinical models, also contributes to market expansion. However, challenges remain. High costs associated with preclinical studies and potential fluctuations in research and development spending by pharmaceutical companies could pose restraints on market growth. Navigating regulatory complexities and ensuring data integrity are crucial for CROs to maintain market competitiveness. The future landscape will likely see a continued shift towards advanced preclinical models and integrated services offered by CROs, driving further consolidation and innovation within the market. Recent developments include: March 2023: GTP Bioways, a contract development and manufacturing organization (CDMO) dedicated to biotherapeutics manufacturing, and Texcell, a contract research organization (CRO) specialized in viral safety, assay development, and GMP banking, partnered to provide comprehensive pre-clinical to clinal phases services to biopharmaceutical companies., November 2023: CEBIS International expanded its preclinical and clinical trials services operations in the North American and Indian markets. With this, the company is committed to advancing its drug development and clinical trial capabilities in a much more efficient manner.. Key drivers for this market are: Increasing Research and Development (R&D) Expenditure Worldwide, Increase in Number of Drugs in Preclinical Trials; High Demand for Medicines Uptake by Chronically Ill Patients. Potential restraints include: Increasing Research and Development (R&D) Expenditure Worldwide, Increase in Number of Drugs in Preclinical Trials; High Demand for Medicines Uptake by Chronically Ill Patients. Notable trends are: The Toxicology Testing Segment is Predicted to Witness Significant Growth Between 2024 and 2029.

raw data and images for the genertion of the figures in the manuscript "Ceruloplasmin administration in the preclinical mouse model of aceruloplasminemia reveals a sex-related variation in biodistribution" by Belloli S, Monterisi C, Rainone P, Coliva A, Zanardi A, Conti A, Caricasole A, Moresco RM, Alessio M. (Published in Communications Biology, 2025)

Open source database used for analyzing and modeling compound interactions with human and animal organ models.Platform for experimental design, data management, and analysis, and to combine experimental data with reference data, to enable computational modeling. Resource for relating in vitro organ model data to multiple biochemical, preclinical, and clinical data sources on in vivo drug effects.

Introduction: There is little evidence regarding the influence of conflicts of interest on preclinical research. This study examines whether industry sponsorship is associated with increased risks of bias and/or effect sizes of outcomes in published preclinical thiazolidinedione (TZD) studies. Methods: We identified preclinical TZD studies published between January 1, 1965, and November 14, 2012. Coders independently extracted information on study design criteria aimed at reducing bias, results for all relevant outcomes, sponsorship source and investigator financial ties from the 112 studies meeting the inclusion criteria. The average standardized mean difference (SMD) across studies was calculated for plasma glucose (efficacy outcome) and weight gain (harm outcome). In subgroup analyses, TZD outcomes were assessed by sponsorship source and risk of bias criteria. Results: Seven studies were funded by industry alone, 17 studies funded by both industry and non-industry, 49 studies funded by non-industry alone and 39 studies had no disclosures. None of the studies used sample size calculations, intention-to-treat analyses, blinding of investigators or concealment of allocation. Most studies reported favourable results (88 of 112) and conclusions (95 of 112) supporting TZD use. Efficacy estimates were significantly larger in six studies sponsored by industry alone (−3.41; 95% CI −5.21, −1.53; I2 = 93%) versus 42 studies sponsored by non-industry sources (−0.97; 95% CI −1.37, −0.56; I2 = 81%; p-value = 0.01). Harms estimates were significantly larger in four studies sponsored by industry alone (5.00; 95% CI 1.22, 8.77; I2 = 93%) versus 38 studies sponsored by non-industry sources (0.30; 95% CI −0.08, 0.68; I2 = 79%; p-value = 0.02). TZD efficacy and harms did not differ by disclosure of financial COIs or risks of bias. Conclusions: Industry-sponsored TZD animal studies have exaggerated efficacy and harms outcomes compared with studies funded by non-industry sources. There was poor reporting of COIs.